Literature DB >> 24833094

Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.

Chengyao Xie1, Yong Han, Lin Fu, Qingchang Li, Xueshan Qiu, Enhua Wang.   

Abstract

CARD recruited membrane associated protein 3 (CARMA3) overexpression has been found in several human cancers. However, its expression pattern and biological roles in human ovarian cancers are not clear. In this study, we examined the expression pattern of CARMA3 in 101 ovarian cancer specimens. We found that 52 (51.5 %) showed CARMA3 overexpression. CARMA3 overexpression positively correlated with tumor histology and advanced FIGO stage. CARMA3 depletion in ovarian cancer cell lines A2780 and HO8910 inhibited ovarian cancer cell proliferation and blocked cell cycle progression. CARMA3 depletion also sensitized ovarian cancer cells to cisplatin-induced cytotoxicity. In addition, Western blot showed that CARMA3 depletion downregulated cyclin D1, cyclin E, and Bcl-2 levels. In conclusion, our data provides evidence that CARMA3 is overexpressed in ovarian cancers and associated with advanced stage. CARMA3 regulates the ovarian cancer cell proliferation, cell cycle progression, and chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24833094     DOI: 10.1007/s13277-014-2070-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation.

Authors:  O Gaide; F Martinon; O Micheau; D Bonnet; M Thome; J Tschopp
Journal:  FEBS Lett       Date:  2001-05-11       Impact factor: 4.124

2.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Alessia Aloisi; Patrizio Damiani; Ludovico Muzii; Giuseppe Scaletta; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Tumour Biol       Date:  2012-08-09

3.  Clinical significance and biological roles of CARMA3 in human bladder carcinoma.

Authors:  Xiaojun Man; Jiani He; Chuize Kong; Yuyan Zhu; Zhe Zhang
Journal:  Tumour Biol       Date:  2014-01-18

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.

Authors:  Kathleen M Darcy; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2010-03-16       Impact factor: 5.482

6.  CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.

Authors:  Linda M McAllister-Lucas; Jürgen Ruland; Katy Siu; Xiaohong Jin; Shufang Gu; David S L Kim; Peter Kuffa; Dawn Kohrt; Tak W Mak; Gabriel Nuñez; Peter C Lucas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

7.  CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-25

8.  Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.

Authors:  Chioniso Patience Masamha; Doris Mangiaracina Benbrook
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

9.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Authors:  Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.

Authors:  Zixuan Li; Lianyue Qu; Qianze Dong; Bo Huang; Haiying Li; Zhongping Tang; Ying Xu; Wenting Luo; Lifeng Liu; Xueshan Qiu; Enhua Wang
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

View more
  12 in total

Review 1.  Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.

Authors:  Rebeca Pérez de Diego; Silvia Sánchez-Ramón; Eduardo López-Collazo; Rubén Martínez-Barricarte; Carolina Cubillos-Zapata; Antonio Ferreira Cerdán; Jean-Laurent Casanova; Anne Puel
Journal:  J Allergy Clin Immunol       Date:  2015-08-12       Impact factor: 10.793

2.  Rare variants in optic disc area gene CARD10 enriched in primary open-angle glaucoma.

Authors:  Tiger Zhou; Emmanuelle Souzeau; Shiwani Sharma; Owen M Siggs; Ivan Goldberg; Paul R Healey; Stuart Graham; Alex W Hewitt; David A Mackey; Robert J Casson; John Landers; Richard Mills; Jonathan Ellis; Paul Leo; Matthew A Brown; Stuart MacGregor; Kathryn P Burdon; Jamie E Craig
Journal:  Mol Genet Genomic Med       Date:  2016-10-03       Impact factor: 2.183

3.  Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Authors:  Yahya I Elshimali; Yong Wu; Hussein Khaddour; Yanyuan Wu; Daniela Gradinaru; Hema Sukhija; Seyung S Chung; Jaydutt V Vadgama
Journal:  J Cancer Res Oncobiol       Date:  2018-02-27

4.  Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer.

Authors:  Xiaoli Xu; Zhiguo Zheng; Lanlan Jia; Shasha Suo; Bowen Liu; Tianning Shao; Qinqing Tu; Yuejin Hua; Hong Xu
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

Review 5.  CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis.

Authors:  J Randall McAuley; Tanner J Freeman; Prasanna Ekambaram; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

Review 6.  CARMA3: Scaffold Protein Involved in NF-κB Signaling.

Authors:  Shilei Zhang; Xin Lin
Journal:  Front Immunol       Date:  2019-02-13       Impact factor: 7.561

7.  CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway.

Authors:  Longfei Peng; Ke He; Zhangjun Cao; Liangkuan Bi; Dexin Yu; Qi Wang; Jinyou Wang
Journal:  Mol Med Rep       Date:  2019-11-21       Impact factor: 2.952

8.  CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.

Authors:  Laura Israël; Anton Glück; Marjorie Berger; Marine Coral; Melanie Ceci; Adeline Unterreiner; Joëlle Rubert; Maureen Bardet; Stefanie Ginster; Alexandra M Golding-Ochsenbein; Kea Martin; Thomas Hoyler; Thomas Calzascia; Grazyna Wieczorek; Rainer Hillenbrand; Stéphane Ferretti; Enrico Ferrero; Frédéric Bornancin
Journal:  Oncogenesis       Date:  2021-04-06       Impact factor: 7.485

9.  Silencing of CARMA3 inhibits bladder cancer cell migration and invasion via deactivating β-catenin signaling pathway.

Authors:  Xiaojun Man; Tao Liu; Yuanjun Jiang; Zhe Zhang; Yuyan Zhu; Zhenhua Li; Chuize Kong; Jiani He
Journal:  Onco Targets Ther       Date:  2019-08-09       Impact factor: 4.147

10.  Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Authors:  Razan Sheta; Magdalena Bachvarova; Marie Plante; Marie-Claude Renaud; Alexandra Sebastianelli; Jean Gregoire; Jamilet Miranda Navarro; Ricardo Bringas Perez; Jean-Yves Masson; Dimcho Bachvarov
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.